7 slides, 1080×1350. Make PNGs and a carousel PDF with npm run reports:cards -- 2026-11-22/sector-snapshot/health-bio.Back to the report

01 / 07Sector of the day

Health & Biotech

Health & Biotech companies raised $20.9B in equity in 2025–2026, 3.1% of all tracked capital, and 2026 has already passed 2025 ($12.6B against $8.4B).

Equity raised, 2025–2026$20.9B2025 $8.4B · 2026 $12.6B
2026 vs 20251.5×2026 to 15 Nov 2026
Companies4059 equity rounds in 2025–2026
02 / 07Top raisers

Isomorphic Labs leads with $2.7B, 13% of the sector's equity in 2025–2026.

  1. Isomorphic LabsLondon$2.7B
  2. MiRusMarietta$1.5B
  3. Parabilis MedicinesCambridge$975M
  4. Neko HealthStockholm$960M
  5. OuraOulu$900M
  6. Earendil LabsWilmington$787M
  7. Eikon TherapeuticsMillbrae$732M
  8. OpenEvidenceCambridge$660M
  9. NeuralinkFremont$650M
  10. Pathos AINew York$602M
03 / 07Biggest rounds

The biggest single round was Isomorphic Labs' $2.1B Series B on 12 May 2026, led by Thrive Capital.

  1. Isomorphic Labs · Series B12 May 2026$2.1B
  2. MiRus · Strategic investment (Boston Scientific)18 May 2026$1.5B
  3. Oura · Funding round of over $900M14 Oct 2025$900M
  4. Earendil Labs · Financing rounds20 Mar 2026$787M
  5. Neko Health · Series C15 Jul 2026$700M
  6. Parabilis Medicines · IPO (Nasdaq: PBLS)9 Jun 2026$670M
  7. Neuralink · Series E2 Jun 2025$650M
  8. Isomorphic Labs · First external funding round31 Mar 2025$600M
04 / 07Where the money went by stage

Series C to E rounds took 34% of the equity; the median round there was $287M.

  1. Seed to Series B16 rounds, median $257M$5.9B
  2. Series C to E25 rounds, median $287M$7.2B
  3. Series F and later6 rounds, median $290M$2.1B
  4. Strategic and unlabelled12 rounds, median $335M$5.8B
05 / 07Most active investors

T. Rowe Price backed 8 Health companies in 2025–2026. For RA Capital Management the sector is 100% of its tracked portfolio.

  1. T. Rowe Price22% of portfolio8 companies
  2. ARCH Venture Partnersled 3 rounds · 86% of portfolio6 companies
  3. GVled 3 rounds · 29% of portfolio6 companies
  4. Fidelityled 2 rounds · 20% of portfolio6 companies
  5. General Catalystled 2 rounds · 15% of portfolio6 companies
  6. Thrive Capitalled 3 rounds · 36% of portfolio5 companies
  7. RA Capital Managementled 1 round · 100% of portfolio5 companies
  8. Blackstoneled 1 round · 25% of portfolio4 companies
  9. Janus Henderson Investorsled 1 round · 67% of portfolio4 companies
  10. Sequoia Capitalled 1 round · 9% of portfolio4 companies
06 / 07Investor groups that repeat here

ARCH Venture Partners and T. Rowe Price invested together in 5 Health rounds, across Kardigan, Mirador Therapeutics, Ollin Biosciences and 1 other.

  1. ARCH Venture PartnersT. Rowe Price5 rounds togetherKardigan, Mirador Therapeutics, Ollin Biosciences, Parabilis Medicines
  2. FidelityT. Rowe Price5 rounds togetherAdvanCell, Kardigan, Mirador Therapeutics, Parabilis Medicines
  3. Kleiner PerkinsThrive Capital5 rounds togetherChai Discovery, NewLimit, OpenEvidence
  4. Sequoia CapitalThrive Capital5 rounds togetherChai Discovery, Neuralink, OpenEvidence
  5. GVThrive Capital5 rounds togetherIsomorphic Labs, OpenEvidence
07 / 07Explore

Every round, valuation and investor of Health & Biotech, on the globe.

vcwithin.com/reports/2026-11-22/sector-snapshot/health-bio

A company and a sector every day · sources on every page